A new study by the University Hospital in Leipzig team published in the Journal of Neuro-Oncology. They studied FOXC1 and the effects of edema around meningiomas after resection.

Long-term survival for patients with newly-diagnosed metastatic cancer has more than doubled ⏫ in the past 40 years.

Join us for our next FREE For Residents, By Residents #RSSwebinar "Updates in Meningioma Management: Dose Escalation and PET-Guided Decision Making" on Weds, 6/24 at noon ET. Register now at therss.org/education/webinar…

In a retrospective cohort of 68 DLBCL patients with partial metabolic response on interim PET after 4 cycles of R-CHOP, PET-directed residual site RT was associated with improved response and PFS. 29 patients received additional R-CHOP risk-adapted pRSRT: • Deauville 4: 24 Gy • Deauville 5: 40 Gy Compared with no RT, pRSRT improved EOT CR: • Overall: 72.4% vs 41.0% • Deauville 5 subgroup: 83.3% vs 22.2% PFS also favored pRSRT: • 2-year PFS: 85.8% vs 52.9% • 5-year PFS: 57.2% vs 44.1% • Multivariable HR 0.26, p=0.018 No statistically significant OS difference was observed, with limited events and no deaths in the RT cohort. Toxicity was generally manageable, though one grade 4 bowel perforation occurred. Although this cohort was treated in the R-CHOP era, the question remains highly relevant in the POLARIX/pola-R-CHP era: when residual PET-avid disease persists despite improved systemic therapy, PET-directed RT may still have a role as a selective consolidation strategy. #lymsm #DLBCL #OncTwitter

LDRT for Greater Trochanteric Pain Syndrome (GTPS) and/or Hip OA Response rate 64% GTPS, 58% Hip OA ↓↓response GTPS symptoms > 1yr, pain flare, hip prosthesis ↓↓response Hip OA BMI > 25, pain flare, >70yo sciencedirect.com/science/ar…

📌 Impact of Radionecrosis and Local Recurrence on Overall Survival After Stereotactic Radiosurgery for Brain Metastases 🧠 🔗 advancesradonc.org/article/S… @ASTRO_org @EJVaios @PeterFecci @MuzamilArshad18 🔹1383 pts 🔸 large, multi-institutional cohort 🔹 Patients diagnosed with LR were diagnosed sooner after SRS than RN (5.8 vs 8.3 months) 🔸 Local recurrence was associated with significantly worse OS than radionecrosis (15.2 vs 40.4 months) 🔹 Patients symptomatic from either LR or RN presented earlier after SRS than asymptomatic patients and had worse OS 🔸 On binomial logistic regression, RN was associated with single fraction SRS (odds ratio [OR] = 0.38, P = 0.012), receipt of immunotherapy after SRS (OR = 0.32, P < 0.014), and a longer interval from SRS (OR = 0.94, P = 0.028).

I am glad these studies are forthcoming. @DanTrifMD providing very thoughtful comments and review @ISRSy Congress #ISRS2026. Dan is helping to lead some of these studies.

Please join us in welcoming @LeilaTchelebi to Penn State Radiation Oncology! We’re excited to have Dr. Tchelebi join the department and look forward to the experience and care she will bring to our patients and team.

🚨🚨 ASCO 2026 Final Results Randomized trial resected brain met Brachytherapy vs Post-Op SRS🚨 - Incredible Surg Bed Control with Brachy (↑↑OS as well) - Surg bed recurrence 12% SRS vs 1% GammaTile

Adjuvant radiotherapy versus observation following curative surgery for early-stage oral squamous cell carcinoma (AREST tria) ASCO 2026

The integration of #DNAMethylation and Copy Number Variation-profiles into the IntS unified risk score offer an enhanced prognostic differentiation of #Meningioma patients - this was the finding from a recent study published in @JNeurooncol. Read here: link.springer.com/article/10…

So, who is going to develop free software to overlay RT DICOM onto follow-up CT imaging after radiotherapy, thereby decreasing patient scanxiety by correlating prior radiotherapy fields w/ diagnostic imaging? Because this paper shows why it matters.🧵👇 @uwradonc @UWRadiology

Celebrating @FSamaan match with colleagues @SSMahaseMD , @MitchMachtay and medical students. Looking forward to seeing Fadi's bright future ahead helping cancer patients. @MayoFL_RORes @ARRO_org

Congratulations to @FSamaan on taking the next step toward a career in Radiation Oncology (Matched to Mayo Clinic Florida)! We also welcomed students interested in becoming Radiation Oncologists to learn more about the field.

What are the outcomes associated w/ re-irradiation for meningiomas? This systematic review and meta-analysis identified 16 studies with 385 pts who received re-☢️ for meningioma. 🔘 Median time from initial RT: 38 mo 🔘 Re-☢️ techniques used: SRS (43%), FSRT (21%), particle therapy (28%) 🔘 Pooled rate of Local Control: 53% (95% CI 48-58%) 🔘 Pooled rate of Overall Survival: 73% (95% CI 67-78%) 🔘 Pooled rate of Symptomatic RT Necrosis: 8% (95% CI 5-11%) 🔘 Pooled rate of Acute Toxicity: 22% (95% CI 17-28%) 🔘 Pooled rate of Chronic Toxicity: 16% (95% CI 11-21%) 🔗 - tinyurl.com/4s2jdw2z @ASTRO_org #radonc #bcsm

New in #practicalRO: Stereotactic Body Radiation Therapy for Non-Spine Bone Metastases: A Case-Based Radiosurgery Society Review. #radonc tinyurl.com/proyliu

New in #practicalRO: Practical Guidelines for Spinal SBRT Post-Treatment Follow-Up: Empirical Consensus from Quebec Oncology Centers. #radonc tinyurl.com/proffabi

Until proper ph. 3 RCT showing at least non-inferiority of vorasidenib vs SOC in terms of survival or QoL, this $500K/yr drug with ORR of 11% and 2yr LF of 40% should not be used in any setting. Ever. Period.

Randomized Trial 1 Yr Seizure prophylaxis after glioma surgery 1 Yr Seizure 47% levetiracetam vs 41% no prophylaxis 1 Yr OS 59% levetiracetam vs 69% no prophylaxis No proven role seizure prophylaxis in glioma academic.oup.com/nop/article…

The entire @Sunnybrook spine #SBRT team has come together to share 17 years of research and clinical observations in this review for @NatRevClinOncol. We are a true multidisciplinary team that have had a singular focus to develop the technique and evidence nature.com/articles/s41571-0…